Appendix 1: East of England (EoE) CCG Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2019-20

High cost drugs excluded from the 2019-20 National Tariff are not commissioned by EoE Clinical Commissioning Groups (CCGs) unless the drugs and indications have approval through local processes.

Please note that the enclosed information reflects the current commissioning arrangements. These arrangements are subject to change in year if commissioning responsibility for particular drugs or services change between Mid and South Essex CCGs and NHSE and / or new local drug policies are introduced or new NICE guidance is published. Any drug and/or a specific indication not listed within the appendix is designated as NOT COMMISSIONED.

The tables in Appendix 1 summarise the policy on the commissioning of drugs and devices (which include drugs). It is coded by a "traffic light" scheme as follows:

	Not commissioned. Where provider Trusts prescribe this treatment the funding responsibility lies with the provider and not the commissioner.
	Approved for use in line with NICE Guidance or where NICE has been converted into a locally agreed protocol or EoE CCG policy. Notification or individual or group prior approval required using proforma or electronic Blueteq® forms as per contract. Clinical evidence of outcomes may be requested by CCGs (in line with local contracts). Funding will not be authorised for patients who do not meet agreed criteria.
	Approved for use in line with locally agreed guidance only. Prior approval, notification proformas or electronic Blueteq® forms should be completed. Indications with other minimum dataset information must be provided on back up data to invoices.
	NHSE commissioning responsibility. CCGs should not consider funding requests for these drugs in these indications / group of patients. For drugs or indications where NHS England is the responsible commissioner the current version of the NHS England drug list should be refered to for the commissioning position, this is located at :- http://www.england.nhs.uk/commissioning/spec-services/key-docs/

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Abatacept	10.1.3	Cytokine modulators	Rheumatoid arthritis after failure of anti-TNF	NICE TA195, August 2010	In line with NICE criteria TA195.	Complete proforma (using agreed local systems)	CCGs commission adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Abatacept	10.1.3	Cytokine modulators	Rheumatoid Arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	NICE TA375 January 2016	In line with NICE TA375 criteria	Complete proforma (using agreed local systems)	CCGs commission adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. NICE TA 375 replaced NICE TA 280
Abatacept	10.1.3	Cytokine modulators	Polyarticular juvenile idiopathic arthritis (2nd line only). Unlicensed use in adults.	NICE TA373 December 2015	In line with NICE TA373 criteria.	Complete proforma (using agreed local systems)	CCG commision adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Abatacept	10.1.3	Cytokine modulators	Active psoriatic arthritis after DMARDs	NICE TA568 Terminated appraisal March 2019	NOT COMMISSIONED	NOT COMMISSIONED	NICE appraisal terminated because the manufacturer does not intend to launch Abatacept for this indication in the UK
Abatacept	10.1.3	Cytokine modulators	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Adalimumab or licensed biosimilar	13.5.3	Cytokine modulators	Psoriasis	NICE TA146, June 2008	In line with NICE criteria TA146.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or licensed biosimilar	1.5.3	Cytokine modulators	Crohn's Disease	NICE TA187, May 2010	In line with NICE TA187	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or licensed biosimilar	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA199, August 2010	In line with NICE criteria TA199.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or licensed biosimilar	1.5.3	Cytokine modulators	Moderate to severe active ulcerative colitis after the failure of conventional therapy	NICE TA329 February 2015	In line with NICE criteria TA329	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or licensed biosimilar	10.1.3	Cytokine modulators	Rheumatoid arthritis	NICE TA375 January 2016 or TA195 August 2010.	In line with NICE criteria TA375 or TA195.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or licensed biosimilar	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	In line with NICE criteria TA383.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or licensed biosimilar	10.1.3	Cytokine modulators	Axial spondyloarthritis (non- radiographic)	NICE TA383 February 2016	In line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or licensed biosimilar	10.1.3	Cytokine modulators	Polyarticular juvenile idiopathic arthritis	NICE TA373 December 2015	In line with NICE TA373 criteria.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or licensed biosimilar	1.5.3 10.1.3 13.5.3	Cytokine modulators	All other indications, licensed or unlicensed.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use of relevant adult TAs.
Andexanet alfa		Factor Xa inhibitor antidote	Reversal of Factor Xa inhibition	NICE ID1101 In development [GID-TA10440] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2019
Afamelanotide		Skin conditions	Prevention of phototoxicity in erythropoietic protoporphyria (EPP).	NICE ID927 In development [GID-HST10009] Publications date TBC	NOT COMMISSIONED	NOT COMMISSIONED	
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	Neovascular (wet) age-related macular degeneration.	NICE TA294, July 2013	In line with NICE TA294.	Complete proforma (using agreed local systems)	NHSE is responsible commissioner for cancer indications.
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	Macular oedema, secondary to CRVO	NICE TA305, February 2014	In line with NICE TA305	Complete proforma (using agreed local systems)	NHSE is responsible commissioner for cancer indications.
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	Diabetic Macular Oedema	NICE TA346 July 2015	In line with NICE TA346	Complete proforma (using agreed local systems)	NHSE is responsible commissioner for cancer indications.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	Macular oedema, secondary to BRVO	NICE TA409 September 2016	In line with NICE TA409	Complete proforma (using agreed local systems)	NHSE is responsible commissioner for cancer indications.
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	Choroidal neovascularisation	NICE TA486 November 2017	In line with NICE TA486	Complete proforma (using agreed local systems)	NHSE is responsible commissioner for cancer indications.
Aflibercept	11.8.2	Subfoveal choroidal neovascularisation	All other indications, licensed or unlicensed.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHSE is responsible commissioner for cancer indications.
Alirocumab	2.12	Lipid-regulating drugs	Primary hypercholesterolaemia (heterozygous familiar and non-familiar) and mixed dyslipidaemia	NICE TA 393 June 2016	In line with NICE TA393 and EoE PAC recommendations.	Complete proforma (using agreed local systems)	
Alirocumab	2.12	Lipid-regulating drugs	Homozygous familial hypercholesterolaemia	No NICE guidance expected	NOT COMMISSIONED	NOT COMMISSIONED	
Alitretinoin	13.5.1	Skin conditions	Severe chronic hand eczema	NICE TA177, August 2009	In line with NICE TA177.	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected.
Darvadstrocel (Alofisel)		Allogenic mesenchymal stem cells	Perianal fistula, complex and refractory to conventional and/or biologic agents in adults with Crohn's disease.	NICE TA556 Jan 2019, not recommended	NOT COMMISSIONED	NOT COMMISSIONED	
Amikacin Liposomal inhalation	5.1.4	Aminoglycosides	Nontuberculous mycobacterial lung infection	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England responsible commissioner for use in CF

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Anakinra	10.1.3	Cytokine modulators	Rheumatoid arthritis	NICE TA72, November 2003 (replaced by NICE CG79, February 2010), not recommended	NOT COMMISSIONED	NOT COMMISSIONED	NHS England responsible commissioner for juvenile arthritis - paediatric, adult onset Stills disease, cropyrin associated periodic syndrome, Stills disease, periodic fevers and autoinflammatory conditions.
Andexanet alfa	2.8.4	Factor Xa inhibitor antidote	Oral anticoagulant reversal agents	NICE ID1101 GID-TA10440 in development. Expected publication date March 2020	NOT COMMISSIONED	NOT COMMISSIONED	
Apremilast	10.1.3	Cytokine modulators	Psoriasis	NICE TA419 November 2016	In line with NICE TA419.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Apremilast	10.1.3	Cytokine modulators	Psoriatic arthritis unresponsive or intolerant to DMARDs	NICE TA433 February 2017	In line with NICE TA433.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Avatrombopag	9.1.4	Platelet disorder drugs	ITP first line	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2019.
Avatrombopag	9.1.4	Platelet disorder drugs	Thrombocytopenia associated with liver disease, pre-surgical procedure.	NICE ID1520 In development [GID-TA10444] Publication expected Feb 2020	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2019.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Aztreonam Lysine nebuliser solution	5.1.2.3	Antibacterial drugs	Cystic Fibrosis	NHSE commissioning policy for CF.	In line with NHS England Policies for CF Policy Ref: A01/P/b Dec 2014 and Policy Ref: 16001/P July 2016	NHS England	Only excluded when given by nebulisation / inhalation. NHS England responsible commissioner for use in CF. GP prescribing not expected.
Aztreonam Lysine nebuliser solution	5.1.2.3	Antibacterial drugs	Bronchiectasis	Bronchiectasis only in line with Local Policies	GPs prescribe for patients subject to local commissioner agreement.	NOT COMMISSIONED	Only excluded when given by nebulisation / inhalation. NHS England responsible commissioner for use in CF
Baricitinib	10.1.3	Cytokine modulators	Moderate to severe active rheumatoid arthritis adult patients who have responded inadequately to intensive therapy with a combination of	NICE TA466 August 2017	In line with NICE TA466.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Bezlotoxumab		Human monoclonal antibody	Prevention of recurrence of Clostridium difficile infection	NICE ID1068 In development [GID-TA10178] Suspended	NOT COMMISSIONED	NOT COMMISSIONED	
Botulinum Toxin A	4.7.4.2	Prophylaxis of migraine	Migraine prophylaxis	NICE TA260, June 2012	In line with NICE TA260	Complete proforma (using agreed local systems)	GP prescribing NOT expected

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	Spasticity (after stroke) where there is a dynamic spastic component (as opposed to contracture) and there are anticipated functional gains in line with Royal College of Physician guidance.	Spasticity (after stroke) - botulinum toxin type A [ID768] - In development [GID-TAG499] Expected publication date: TBC	In line with PAC recommendations	Complete proforma (using agreed local systems)	GP prescribing NOT expected
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	Hypersalivation associated with neurological conditions (including Hirschsprung's disease).	NICE ID1150 In development [GID-TA10296] Publication expected October 2019	In line with PAC recommendations.	NOT COMMISSIONED	GP prescribing NOT expected

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	Chronic anal fissure, severe blepharospasm, hemifacial spasm, cervical dystonia (spasmodic torticollis), focal spasticity in upper and lower limb in adults (causes other than stroke), hyperhidrosis of the axillae, dysphagia caused by achalasia and overactive bladder.,	No NICE guidance anticipated	In line with PAC recommendations.	Complete proforma (using agreed local systems)	GP prescribing NOT expected.NHS England is responsible commissioner for focal spasticity in children. Treatment of spasticity in paediatric cerebral palsy is commissioned by NHSE at specialist centres only. Intravesical use in spinal injury commissioned by NHSE.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	Chronic sialorrhoea in adults and children, associated with neurological conditions such as cerebral palsy (CP), Parkinson's disease (PD), stroke and traumatic brain injury (TBI) (licence extension).	No NICE guidance anticipated	NOT COMMISSIOINED	NOT COMMISSIONED	License extension expected 2019. GP prescribing NOT expected.NHS England is responsible commissioner for focal spasticity in children. Treatment of spasticity in paediatric cerebral palsy is commissioned by NHSE at specialist centres only. Intravesical use in spinal injury commissioned by NHSE.
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	Laryngeal dystonia (spasmodic dystonia), hydradenitis suppurative, mechanical neck disorders, correction of strabismus (squint) in paediatrics, dysphagia (causes other than achalasia), Raynaud's Disease, Massateric Hypertrophy.	No NICE guidance anticipated	NOT COMMISSIOINED	NOT COMMISSIONED	In line with negative PAC recommendations
Botulinum Toxin A	4.9.3	Essential tremor, chorea, tics and related disorders	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Botulinum Toxin B	4.9.3	Torsion, dystonias and other involuntary movements	Spasmodic torticollis (Cervical dystonia)	No NICE guidance anticipated	In patients resistant to Botulinum Toxin A for cervical dystonia.	NOT COMMISSIONED	
Brodalumab	13.5.3	Drugs affecting the immune response	Plaque psoriasis, moderate-to-severe.	NICE TA511 March 2018	In line with NICE TA511	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Brolucizumab	10.1.3	Cytokine modulators	Neovascular (wet) age-related macular degeneration (AMD)	NICE ID1254 Proposed [GID-TA10455] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2020.
Cannabidiol		Cannabinoids	Seizures associated with Dravet syndrome	NICE ID1211[GID-TA10274] Expected publication date: December 2019	NOT COMMISSIONED	NOT COMMISSIONED	Dravet/Lennox Gastaut syndrome is NHS England specialised service
Cannabidiol		Cannabinoids	Seizures associated with Lennox - Gastautsyndrome	NICE ID1308[GID-TA10410] Expected publication date: December 2019	NOT COMMISIONED	NOT COMMISSIONED	Dravet/Lennox Gastaut syndrome is NHS England specialised service
Cannabidiol		Cannabinoids	All other indications	No NICE guidance expected.	NOT COMMISSIONED	NOT COMMISSIONED	Dravet/Lennox Gastaut syndrome is NHS England specialised servise
Caplacizumab		Anti-von Willebrand factor (vWF) nanobody	Acquired thrombotic thrombocytopenic purpura (aTTP)	NICE ID1185 In development [GID-TA10361] Publication date August 2019	NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Certolizumab Pegol	10.1.3	Cytokine modulators	Rheumatoid Arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	NICE TA375 January 2016	In line with NICE TA375	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Certolizumab Pegol	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383, February 2016	In line with NICE TA383.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Certolizumab Pegol	10.1.3	Cytokine modulators	Axial spondyloarthritis (non radiographic)	NICE TA383, February 2016	In line with NICE TA383.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Certolizumab Pegol	10.1.3	Cytokine modulators	Rheumatoid arthritis after TNF inhibitor	NICE TA415 Oct 2016	In line with NICE TA415	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Certolizumab Pegol	10.1.3	Cytokine modulators	Active psoriatic arthritis after DMARDs	NICE TA445 May 2017	In line with NICE TA445	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Certolizumab Pegol	10.1.3	Cytokine modulators	Early progressive rheumatoid arthritis, untreated by DMARDs	Negative NICE TA375, January 2016	NOT COMMISSIONED	NOT COMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Certolizumab Pegol	10.1.3	Cytokine modulators	Moderate to severe plaque psoriasis	NICE TA 574 April 2019	In line with NICE TA 574	Complete proforma (using agreed local systems)	CCG commission Adults GP prescribing NOT expected
Certolizumab Pegol	10.1.3	Cytokine modulators	All other indications, licensed or unlicensed.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMISSIONED	
Colistimethate sodium powder for nebulisation	5.1.7	Antibacterial drugs	Cystic Fibrosis		NHSE Policy - Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014	NHS England	Only excluded when given by nebulisation/inhalation.
Colistimethate sodium dry powder for inhalation (Colobreathe®)	5.1.8	Antibacterial drugs	Cystic Fibrosis	NICE TA276, March 2013.	NHSE Policy - Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014	No GP prescribing of Colobreathe® as Patient Access Scheme not available in primary care.	Only excluded when given by nebulisation/inhalation.
Collagenase	10.1.3	Enzymes	Peyronie's disease (PsD)	No NICE guidance anticipated.	NOT COMMISSIONED.	NOT COMMISSIONED.	
Collagenase	10.1.3	Enzymes	Dupuytren's Contracture	NICE TA459 July 2017	In line with NICE TA459	Complete proforma (using agreed local systems)	Only excluded from tariff when used in outpatients
Deferasirox	9.1.3	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	PAC recommendation (not recommended)	Only in line with Local Policies	NOT COMMISSIONED	NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Deferiprone	9.1.3	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	PAC recommendation (not recommended)	Only in line with Local Policies	NOT COMMISSIONED	NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required.
Desferrioxamine	9.1.3	Iron overload	Anaemia related to chronic iron overload for myelodysplastic syndrome only	PAC recommendation (not recommended)	Only in line with Local Policies	NOT COMMISSIONED	NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required.
Dexamethasone intravitreal implant	11.4.1	Macular oedema	Macular oedema secondary to retinal vein occlusion.	NICE TA229, July 2011.	In line with NICE TA229.	Complete proforma (using agreed local systems)	
Dexamethasone intravitreal implant	11.4.1	Macular oedema	Diabetic Macular Oedema	NICE TA349 July 2015	In line with NICE TA349	Complete proforma (using agreed local systems)	
Dexamethasone intravitreal implant	11.4.2	Macular oedema	Non-infectious uveitis (unilateral)	NICE TA460 July 2017	In line with NICE TA460 criteria.	Complete proforma (using agreed local systems)	
Dibotermin alfa		Bone morphogenetic protein	Acute tibia fractures	No NICE guidance anticipated.	Only in line with Local Policies (PAC policy)	Complete proforma (using agreed local systems)	NHS England responsible commissioner for complex spinal surgery NHSE policy 16063.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Digoxin immune fab	2.1.1	Poisoning	Life-threatening digoxin toxicity.	National Poisons Centre Guidelines.	Only commissioned in line with National Poison Centres guidelines.	Local Commissioner to be notified / invoiced when used.	Available on named patient basis only in hospitals.
Dimethyl fumarate	13.5.2	Preparations for psoriasis	Moderate to severe plaque psoriasis	NICE TA475 September 2017	In line with NICE TA475	Complete proforma (using agreed local systems)	NHS England is responsible commissioner for Multiple Sclerosis.
Dupilumab injection	13	Anti-interleukin -4 and -13 receptor monoclonal antibody	Moderate-to-severe atopic dermatitis	TA534 August 2018	In line with NICE TA534	Complete proforma (using agreed local systems)	NHS England responsible commissioner for asthma indication.
Dupilumab injection	13	Anti-interleukin -4 and -13 receptor monoclonal antibody	Severe asthma	NICE [GID-TA10276] Publication date July 2020	NOT COMMISSIONED	NOT COMMISSIONED	UK launch plans unknown.
Dupilumab injection	13	Anti-interleukin -4 and -13 receptor monoclonal antibody	Nasal cronic rhinosinusitis with nasal polyps	NICE ID1179 Proposed [GID-TA10450] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted launch 2020
Eculizumab	10	Recombinant humanised monoclonal antibody.	Relapsing neromyelitis optica	NICE ID1271 Proposed [GID-TA10469] Expected publication date: TBC	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for Atypical haemolytic uremic syndrome (aHUS), Paroxysmal nocturnal haemoglobinuria (PNH), , C3 glomerulopathy post transplant

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Eculizumab	10	Recombinant humanised monoclonal antibody.	Myasthenia Gravis (MG), generalised, refractory, in patients who are anti-acetylcholine receptor antibody-positive	NICE ID1064 Due May 2018 but currently suspended	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for Atypical haemolytic uremic syndrome (aHUS), Paroxysmal nocturnal haemoglobinuria (PNH), , C3 glomerulopathy post transplant
Eltrombopag	9.1.4	Platelet disorder drugs	Chronic idiopathic thrombocytopenic purpura (ITP)	NICE TA293, July 2013	In line with NICE TA293.	Complete proforma (using agreed local systems)	GP prescribing NOT expected. NHS England are the responsible commissioner for use in paediatrics
Eltrombopag	9.1.4	Platelet disorder drugs	Thrombocytopenia in adult patients with chronic hepatitis C virus infection	No NICE guidance anticipated.	Only in line with Local Policies/PAC recommendations.	NOT COMMISSIONED	GP prescribing NOT expected.PAC recommendations published Sept 2014.
Eltrombopag	9.1.4	Platelet disorder drugs	Severe aplastic anaemia (SAA) refractory immunosuppressive therapy	NICE TA382 terminated appraisal, January 2016. NICE unable to make a recommendation.	NOT COMMISSIONED.	NOT COMMISSIONED.	
Eltrombopag	9.1.4	Platelet disorder drugs	Untreated severe aplastic anaemia	NICE ID1198 suspended	NOT COMMISSIONED.	NOT COMMISSIONED.	Unlicensed indication.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Erenumab		Humanised monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP)	Migraine, prevention in adults.	NICE ID1188 [GID-TA10302] Expected publication date: July 2019	NOT COMMISSIONED	NOT COMMISSIONED	
Erythropoietins	9.1.3	Drugs used in renal anaemias	Hypoplastic, haemolytic and renal anaemias	No NICE guidance anticipated.	NHS England	NHS England	Only excluded when used in conjunction with renal dialysis. NHS England is the responsible commissioner for dialysis induced anaemia.
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Rheumatoid Arthritis	NICE TA375 January 2016 or TA195 August 2010.	In line with NICE criteria TA375 or TA195.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	In line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Axial spondyloarthritis (non radiographic)	NICE TA383 February 2016	In line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. , TA143, TA199)
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA199, August 2010	In line with NICE TA199.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Psoriasis	NICE TA103, July 2006	In line with NICE TA103.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	Polyarticular juvenile idiopathic arthritis or Enthesitis-related JIA or Psoriatic JIA. Unlicensed use in adults.	NICE TA373 Dec 2015	In line with NICE TA373 criteria.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373
Etanercept or licensed biosimilar	10.1.3	Cytokine modulators	All other indications, licensed or unlicensed.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use.
Evolocumab	2.12	PCSK9 Monoclonal Antibody Inhibitor	Primary hypercholesterolaemia (heterozygous familiar and non-familiar) and mixed dyslipidaemia	NICE TA394, June 2016.	In line with NICE TA394 and EoE PAC recommendations	Complete proforma (using agreed local systems)	CCG commission Primary non-familial hypercholesterolaemia or mixed dyslipidaemia. NHSE is responsible commissioner for Homozygous familial hypercholesterolemia
Evolocumab	2.12	PCSK9 Monoclonal Antibody Inhibitor	Prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease.	No NICE guidance anticipated.	To be confirmed	To be confirmed	
Fidaxomicin	5.1.7	Antibacterials	C. difficile associated diarrhoea (CDAD) in adults		NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Fidaxomicin	5.1.8	Antibacterials	C. difficile associated diarrhoea (CDAD) in children		NOT COMMISSIONED	NOT COMMISSIONED	License extension expected 2020.
Fluocinolone acetonide intravitreal implant	11.4.1	Macular oedema	Chronic diabetic macular oedema	NICE TA301, November 2013 Under review NICE ID1421 In development [GID-TA10379] Publication date TBC	In line with NICE TA301.	Complete proforma (using agreed local systems)	
Fluocinolone acetonide intravitreal implant	11.4.2	Corticosteroid implant	Non-infectious posterior uveitis that is sight threatening, second-line.	NICE ID1039 In development [GID-TA10368] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	
Fomepizole		Poisoning	Poisoning	National Poisons Centre Guidelines	Only commissioned in line with National Poison Centres guidelines.	Local Commissioner to be notified when used.	
Fremanezumab		Humanised monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP).	Episodic and chronic migraine prevention in adults.	NICE ID1368 In development [GID-TA10339]. Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	
Fremanezumab		Humanised monoclonal antibody that inhibits calcitonin gene-related peptide	Episodic cluster headache in adults, prevention (licence extension).	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Galcanezumab	4	Monoclonal-antibody, calcitonin gene-related peptide antagonist	Prevention of chronic or episodic migraine.	NICE ID1372. Proposed [GID-TA10454] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	
Galcanezumab	4	Monoclonal-antibody, calcitonin gene-related peptide antagonist	Prevention of cluster headache	NICE ID1212. Proposed [GID-TA10425] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	
Golimumab	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA220 April 2011	In line with NICE TA220.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Golimumab	10.1.3	Cytokine modulators	Rheumatoid arthritis	NICE TA375 Jan 2016 or TA225 June 2011	In line with NICE TA375 or TA225	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Golimumab	1.5.3	Cytokine modulators	Moderate to severe ulcerative colitis-second line	NICE TA329 Feb 2015	In line with NICE TA329	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Golimumab	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	In line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Golimumab	10.1.3	Cytokine modulators	Axial spondyloarthritis (non-radiographic)	NICE TA497 January 2018	In line with NICE TA497	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected..
Golimumab	10.1.3	Cytokine modulators	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Guselkumab	13.5.3	Drugs affecting the immune response.	Plaque psoriasis, moderate-to-severe	NICE TA521 June 2018	In line with NICE TA521	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected..

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Idarucizumab	2.8.4	Oral anticoagulant reversal agents	Reversal agent for dabigatran	No NICE guidance anticipated.		Local Commissioner to be notified / invoiced when used.	
Iloprost	2.5.1	Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension	Critical limb ischaemia	No NICE guidance anticipated.	Only in line with Local Policies	NOT COMMISSIONED	NHSE commissioned when used for pulmonary arterial hypertension at specialist centres.
Infliximab or licensed biosimilar	1.5.3	Cytokine modulators	Crohn's Disease	NICE TA187, May 2010	In line with NICE TA187	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	10.1.3	Cytokine modulators	Rheumatoid Arthritis	NICE TA375 Jan 2016 or TA195 Aug 2010.	In line with NICE TA375 or TA195.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Infliximab or licensed biosimilar	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA199, August 2010	In line with NICE TA199.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab or licensed biosimilar	13.5.3	Cytokine modulators	Psoriasis (adults)	NICE TA134, January 2008	In line with NICE TA134.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Infliximab or licensed biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis (acute exacerbations)	NICE TA163, December 2008	In line with NICE TA163.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Infliximab or licensed biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis - 2nd line for moderate to severely active	NICE TA329 Feb 2015	In line with NICE TA329	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Infliximab or licensed biosimilar	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	If treatment is started with the least expensive infliximab product in line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected.
Infliximab or biosimilar	10.1.3	Cytokine modulators	JIA (unlicensed indication)	Patient currently responding to treatment.	Continuation and discontinuation in line with NHSE policy E03/P/d (EO3X04). No initiation in adults	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Infliximab or licensed biosimilar	10.1.3	Cytokine modulators	Axial spondyloarthritis (non- radiographic). Unlicensed indication.	Not considered in NICE TA383 February 2016.	NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab or licensed biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis (Sub-acute manifestations)	NICE TA329 Feb 2015 Not recommended	NOT COMMISSIONED	NOT COMMISSIONED	
Infliximab or licensed biosimilar	1.5.3 10.1.3 13.5.3	Cytokine modulators	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Ixekizumab	13.4.2	Humanized anti–interleukin-17 monoclonal antibody	Plaque psoriasis	NICE TA442 April 2017	In line with NICE TA 442	Complete proforma (using agreed local systems)	Adults only, GP prescribing NOT expected.
Ixekizumab	10.1.3	Humanized anti–interleukin-17 monoclonal antibody	Psoriatic arthritis	NICE TA537 August 2018	In line with NICE TA537	Complete proforma (using agreed local systems)	Adults only, GP prescribing NOT expected.
Ixekizumab	10.1.3	Humanized anti–interleukin-17 monoclonal antibody	Axial spondyloarthritis after NSAIDs	NICE ID1532 [GID-TA10458] Expected publication date: TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2020

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Ketorolac with Phenylephrine		Retinal disorders/intraocular lens replacement surgery	Intraocular lens replacement surgery	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Licensed. UK launch plans not known.
Lanreotide	8.3.4.3	Somatostatin Analogues	Cancer, acromegaly.	No NICE guidance anticipated.	NHS England	NHS England	NHS England is responsible commissioner for cancer indications and congenital hyperinsulinism and for acromegaly but only when prescribed in a specialist centre.
Levofloxacin Solution for Inhalation	5.1.2	Antibacterial drugs	Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with CF	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Only excluded when given by nebulisation / inhalation. NHS England is the responsible commissioner for cystic fibrosis only when prescribed in a specialist centre.
Liothyronine injection		Other endocrine drugs	Myxoedema coma	No NICE guidance anticipated.	TBC	TBC	
Liothyronine injection		Other endocrine drugs	Thyroid replacement in patients who are long term nil by mouth.	No NICE guidance anticipated.	TBC	TBC	Unlicensed indication.
Liothyronine injection		Other endocrine drugs	Management of organ donor patients post brain death.	No NICE guidance anticipated.	TBC	TBC	Unlicensed indication.
Lusutrombopag		Platelet Disorder Drugs	Thrombocytopenia in adults with chronic liver disease prior to elective procedures	NICE ID1520 In development [GID-TA10444] Publication expected Feb 2020	NOT COMMISSIONED	NOT COMMISSIONED	Licensed but not launched.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Mannitol	3.7	Mucolytics	Cystic Fibrosis	NICE TA266 November 2012	NHSE Policy - Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014. GPs prescribe for patients subject to local commissioner agreement.	NHS England	NHSE. Only excluded when given by nebulisation / inhalation. GP prescribing not expected.
Mannitol	3.7	Mucolytics	Indications other than cystic fibrosis.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Mepolizumab		Fully humanised IgG monoclonal antibody specific for interleukin 5	Chronic obstructive pulmonary disease	NICE ID1327 publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted launch date unknown. NHS England responsible commissioner for asthma indication.Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss syndrome) - NHSE likely to be responsible commissioners.
Mexiletine		Neuromuscular disorders	Non-dystrophic myotona		NHS England	NHS England	Excluded HCD for neuromuscular disorder only. NHS England is responsible commissioner for neuromuscular disorder.
Ocriplasmin	11.8.2	Retinal disorders	Vitreomacular traction including those associated with macular holes.	NICE TA297 Oct 2013	In line with NICE TA297	Complete proforma (using agreed local systems)	GP prescribing NOT recommended.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Octreotide	8.3.4.3	Somatostatin Analogues	Non cancer indications		Only in line with Local Policies	Complete proforma (using agreed local systems)	NHS England responsible commissioner for cancer, congenital hyperinsulinaemia and acromegaly but only when prescribed in a specialist centre.
Omalizumab	3.4.2	Allergen Immunotherapy	Previously treated chronic spontaneous urticaria	NICE TA339 June 2015	In line with NICE TA339	Complete proforma (using agreed local systems)	NHS England responsible for asthma indication
Pitolisant	4.1.1	Hypnotics and anxiolytics	Narcolepsy with or without cataplexy	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Pitolisant	4.1.1	Hypnotics and anxiolytics	Obstructive sleep apnoea	NICE ID1065 [GID-TA10385] Expected publication date: TBC	NOT COMMISIONED	NOT COMMISSIONED	
Ranibizumab	11.8.2	Neovascularisation	Neovascular (wet) age-related macular degeneration	NICE TA155, August 2008	In line with NICE TA155.	Complete proforma (using agreed local systems)	GP prescribing NOT expected.
Ranibizumab	11.8.2	Neovascularisation	Diabetic Macular Oedema	NICE TA274, Feb 2013	In line with TA274.	Complete proforma (using agreed local systems)	GP prescribing NOT expected.
Ranibizumab	11.8.2	Neovascularisation	Macular oedema (retinal vein occlusion)	NICE TA283, May 2013	In line with TA283.	Complete proforma (using agreed local systems)	GP prescribing NOT expected.
Ranibizumab	11.8.2	Neovascularisation	CNV due to pathological myopia	NICE TA298, November 2013	In line with TA298.	Complete proforma (using agreed local systems)	GP prescribing NOT expected.
Ranibizumab	11.8.3	Neovascularisation	Moderately-severe to severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) 2019	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Licensed extension predicted 2019

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Ranibizumab injection	11.8.2	Neovascularisation	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Risankizumab		Humanised IgG1 Monoclonal antibody	Chronic plaque psoriasis moderate-severe	ID1398 In development [GID-TA10349] Expected publication August 2019	NOT COMMISSIONED	NOT COMMISSIONED	
Rituximab or licensed biosimilar	10.1.3	Cytokine modulators	Rheumatoid Arthritis after failure of TNF inhibitor	NICE TA195, Aug 2010	In line with NICE TA195.	Complete proforma (using agreed local systems)	NHS England responsible commissioner for ANCA-positive vasculitis, cancer, haemophilia, paediatric indications, graft vs host disease, SLE, myositis, neuromyelitis optica, renal disease and transplants indications, PSS, polyneuropathy, connective tisse/interstitial lung disease, immunodeficiency, immunogloblin related, pemphigus vulgaris/pemphigoid disease.
Rituximab or licensed biosimilar	10.1.3	Cytokine modulators	Rheumatoid arthritis (first line)	No NICE guidance anticipated.	Only in line with Local Policies	Complete proforma (using agreed local systems)	
Rituximab or licensed biosimilar	10.1.3	Cytokine modulators	ITP	No NICE guidance anticipated.	Only in line with Local Policies	Complete proforma (using agreed local systems)	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Rituximab or licensed biosimilar	10.1.3	Cytokine modulators	Refractory vasculitis		Only in line with Local Policies	Complete proforma (using agreed local systems)	
Rituximab or biosimilar	10.1.3	Cytokine modulators	JIA (unlicensed indication)	Patient currently responding to treatment,transitioned from the NHS England paediatric service	Continuation and discontinuation in line with NHSE policy E03/P/d (EO3X04). No initiation in adults	Complete proforma (using agreed local systems)	
Rituximab or licensed biosimilar	10.1.3	Cytokine modulators	All other indication, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Romiplostim	9.1.4	Platelet Disorder Drugs	ITP	NICE TA221 April 2011	In line with NICE TA221.	Complete proforma (using agreed local systems)	GP prescribing NOT expected. NHS England are the responsible commissioner for use in paediatrics
Romosozumab		Humanised monoclonal antibody, sclerostin inhibitor	Osteoporosis in men and postmenopausal women	Non-bisphosphonates for treating osteoporosis NICE ID901 In development [GID-TA10072] Expected publication September 2019	NOT COMMISSIONED	NOT COMMISSIONED	
Sarilumab	No BNF category	Cytokine modulators	Moderately to severely active rheumatoid arthritis (RA)	NICE TA485 November 2017	In line with NICE TA485.	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Secukinumab	10.1.3	Cytokine modulators	Chronic plaque psoriasis moderate-severe after failed conventional therapies	NICE TA350 July 2015	In line with NICE TA350	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab	10.1.3	Cytokine modulators	Ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	NICE TA407 September 2016	In line with NICE TA407	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab		Cytokine modulators	Psoriatic arthritis, second line	NICE TA455 May 2017	In line with NICE TA407	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab	10.1.3	Cytokine modulators	Axial - spondyloarthritis (non-radiographic)	NICE ID1419 Proposed [GID-TA10457] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2020
Secukinumab		Cytokine modulators	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Siltuximab	10.1.3	Cytokine modulators	Castleman's disease	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Sodium oxybate	4.1	Hypnotics and anxiolytics	Narcolepsy with cataplexy (adults)		EoE PAC policy - Low priority and not routinely funded. Existing patients may continue until they or their clinician discontinue.	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use.
Solriamfetol	4.1	Hypnotics and anxiolytics	Obstructive sleep apnoea syndrome (OSAS)-associated excessive daytime sleepiness (EDS)	ID1499 Proposed [GID-TA10430] Publication date TBC	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch 2020
Somatropin (adults)	6.5.1	Growth Hormone or Growth Hormone Receptor Antagonist	Adults with growth hormone deficiency	NICE TA64 August 2013	In line with NICE TA64	Complete proforma (using agreed local systems)	Local Commissioner
Somatropin (children)	6.5.1	Growth Hormone or Growth Hormone Receptor Antagonist	Growth failure in children	NICE TA188, May 2010	In line with NICE TA188 and EoE PAC recommendations	Complete proforma (using agreed local systems)	Local Commissioner and GOSH NB: Shared care arrangements with GPs in place.
Teriparatide	6.6.1	Drugs affecting bone metabolism	Secondary prevention of osteoporotic fragility fractures in postmenopausal women.	NICE TA161 Jan 2011. Note: NICE review Non-bisphosphonates for treating osteoporosis [ID901] In development [GID-TA10072] September 2019	In line with NICE TA161 guidance or locally agreed protocols.	Complete proforma (using agreed local systems)	GP prescribing NOT expected. Local Commissioner. NHSE responsible commissioner for male and juvenile osteoporosis.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Teriparatide	6.6.1	Drugs affecting bone metabolism	Treatment of osteoporosis associated with glucocorticoids	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Tildrakizumab	13	Human interleukin-23 antagonist	Chronic plaque psoriasis in adults, moderate-to-severe	NICE TA575, April 2019	In line with NICE TA575	Complete proforma (using agreed local systems)	
Tobramycin (Tobi® / Bramitob®) nebuliser solution	5.1.4	Antibacterial Drugs	Cystic Fibrosis		NHSE Policy - Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b	NHS England commissioning responsibility. No GP prescribing	Only excluded when given by nebulisation / inhalation.
Tobramycin (Tobi® Podhaler) dry powder for inhalation	5.1.5	Antibacterial Drugs	Cystic Fibrosis	NICE TA276, March 2013.	NHSE Policy - Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b	No GP prescribing of Tobi® Podhaler as Patient Access Scheme not available in primary care. NHS England commissioning responsibility.	Only excluded when given by nebulisation / inhalation.
Tocilizumab	10.1.3	Cytokine modulator	Rheumatoid Arthritis	NICE TA247 Feb 2012 or TA 375 Jan 2016	In line with NICE TA247 or TA375	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, paediatric juvenile arthritis (NICE TA 373 and TA238) Takayasu arteritis and Giant cell arteritis.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Tocilizumab	10.1.3	Cytokine modulators	Polyarticular juvenile idiopathic arthritis	NICE TA373 Dec 2015	In line with NICE TA373 criteria and continuation in young adults tranisitioning from NHS England paeds service	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, paediatric juvenile arthritis (NICE TA 373 and TA238) Takayasu arteritis and Giant cell arteritis.
Tocilizumab	10.1.3	Cytokine modulator	All other indications, licensed or unlicensed.	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, paediatric juvenile arthritis (NICE TA 373 and TA238) Takayasu arteritis and Giant cell arteritis.
Tofacitinib	10.3.1	Cytokine modulator	Rheumatoid arthritis, moderate-to-severe, in patients not responding to DMARDs or methotrexate.	NICE TA480 October 2017	In line with NICE TA480	Complete proforma (using agreed local systems)	Adults only. GP prescribing not expected.
Tofacitinib	10.3.1	Cytokine modulator	Psoriatic arthritis second-line following failure of conventional DMARDs, third-line following failure of biological DMARDs	NICE TA543 October 2018	In line with NICE TA543	Complete proforma (using agreed local systems)	Adults only. GP prescribing not expected

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Tofacitinib	10.3.1	Cytokine modulator	Moderate-to-severe active ulcerative colitis in adults, following failure of conventional therapy.	NICE TA547 November 2018	In line with NICE TA547	Complete proforma (using agreed local systems)	Adults only. GP prescribing not expected
Tolvaptan	6.5.2	Vasopressin V2-receptor antagonist	Autosomal dominant polycystic kidney disease, stage 2 or 3, rapidly progressing	NICE TA358 October 2015	In line with NICE TA358.	Complete proforma (using agreed local systems)	NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy.
Tolvaptan	6.5.2	Vasopressin V2-receptor antagonist	Hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients who do not require	No NICE guidance anticipated.	In line with PAC recommendations.	NOT COMMISSIONED	NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy.
Tolvaptan	6.5.2	Vasopressin V2-receptor antagonist	Hyponatraemia from other causes and other endocrine uses	No NICE guidance anticipated.	Only in line with Local Policies	NOT COMMISSIONED	NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy.
Tolvaptan	6.5.2	Vasopressin V2-receptor antagonist	All other indications, licensed or unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy.
Upadacitinib	10	Janus kinase (JAK) inhibitor	Rheumatoid arthritis (RA) with inadequate response to either methotrexate or TNF inhibitors	NICE ID1400 Proposed [GID-TA10389] Publication date March 2020	NOT COMMISSIONED	NOT COMMISSIONED	Predicted launch 2020. It is anticipated that NHSE is responsible commissioner for paediatric use.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Ustekinumab	13.5.3	Drugs affecting the immune response	Psoriasis moderate to severe	NICE TA180, Sept 2009	In line with NICE TA180.	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected.
Ustekinumab	10.1.3	Drugs affecting the immune response	Psoriatic arthritis	NICE TA340 June 2015	In line with NICE TA340	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected.
Ustekinumab	1.5.3	Drugs affecting the immune response	Ustekinumab for moderately to severely active Crohn's disease after previous treatment	TA456 July 2017	In line with NICE TA456.	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected.
Ustekinumab	13.5.3	Drugs affecting the immune response	Ulcerative colitis, moderate-to-severe active disease, second-line	NICE ID1511 In development [GID-TA10434] Expected publication March 2020	NOT COMMISSIONED	NOT COMMISSIONED	
Ustekinumab	13.5.3	Drugs affecting the immune response	All other indications, licensed and unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Valbenazine	4	Vesicular monoamine transporter-2 inhibitor	Tardive dyskinesia in adults	No NICE guidance anticipated	NOT COMMISSIONED	NOT COMMISSIONED	Launch date not known.

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Vedolizumab	1.5.3	Drugs affecting the immune response	Moderate to severe ulcerative colitis - second line after conventional therapy or TNF inhibitor	NICE TA342 June 2015	In line with NICE TA342 and locally agreed patient pathway	Complete proforma (using agreed local systems)	Adults only. GP prescribing not expected
Vedolizumab	1.5.3	Drugs affecting the immune response	Crohn's disease second line after conventional therapy and TNF inhibitors	NICE TA352 Aug 2015	In line with NICE TA352	Complete proforma (using agreed local systems)	Adults only. GP prescribing not expected
Vedolizumab	13.5.3	Drugs affecting the immune response	All other indications, licensed and unlicensed.		NOT COMMISSIONED	NOT COMMISSIONED	
Verteporfin	11.8.2	Subfoveal choroidal neovascularisation	Photodynamic therapy for wet age-related degeneration.	NICE guideline [NG82] Jan 2018 (replaces NICE TA68, September 2003)	In line with NG82.	NOT COMMISSIONED	

High cost devices and listed procedures 2019/20

Return to contents

Device	Comments/Notes
3 dimensional mapping and linear ablation catheters used for complex cardiac ablation procedures	Includes consumables that are required uniquely for the deployment of the device
Aneurysm coils	Separated aneurysm coils and flow diverters for intracranial aneurysms. Includes consumables that are required uniquely for the deployment of the device
Bespoke orthopaedic prostheses	Bespoke prostheses designed and manufactured for individual patients plus modular limb salvage replacements for femur or shoulder (non CE marked). Includes consumables that are required uniquely for the deployment of the device
Biological mesh, including synthetic equivalents	Synthetic equivalents included. Includes consumables that are required uniquely for the deployment of the device
Bone Anchored Hearing Aids and Middle Ear Implants	Includes consumables that are required uniquely for the deployment of the device
Bone Growth Stimulators	Includes consumables that are required uniquely for the deployment of the device
Carotid, iliac and renal stents	Includes embolic protection devices. Includes consumables that are required uniquely for the deployment of the device
Lengthing nails for Limb Reconstruction and Circular external fixator frame	Includes consumables that are required uniquely for the deployment of the device
Consumables associated with per oral single operator cholangioscope	Includes consumables that are required uniquely for the deployment of the device
Deep brain, vagal, sacral, spinal cord and occipital nerve stimulators	Includes Lumbar Multifidus Restorative Neurostimulator and Spinal cord stimulator (patient remote controller). Includes consumables that are required uniquely for the deployment of the device
Devices used in connection with pulmonary artery banding	Includes consumables that are required uniquely for the deployment of the device
Drug-eluting peripheral angioplasty balloon	Includes consumables that are required uniquely for the deployment of the device
Endovascular stent graft	Includes aortic stent grafts, endovascular fixation devices for endovascular stent grafts and trans-jugular intrahepatic port-systemic shunt (TIPSS). Includes consumables that are required uniquely for the deployment of the device
Flow diverters for intracranial aneurysms	Includes consumables that are required uniquely for the deployment of the device
ICD (Implantable Cardioverter-Defibrillator)	Includes consumables that are required uniquely for the deployment of the device
ICD with CRT (Cardiac Resynchronisation Therapy) capability	Includes consumables that are required uniquely for the deployment of the device
Insulin pumps and pump consumables	Includes consumables that are required uniquely for the deployment of the device
Intracranial stents	Includes consumables that are required uniquely for the deployment of the device
Intrathecal drug delivery pumps	Includes consumables that are required uniquely for the deployment of the device
Maxillofacial bespoke prostheses	Includes consumables that are required uniquely for the deployment of the device
Occluder, Vascular, Appendage and Septal devices	Includes consumables that are required uniquely for the deployment of the device
Percutaneous valve repair and replacement devices	Includes devices for TAVI. Includes consumables that are required uniquely for the deployment of the device
Peripheral vascular stents	Includes peripheral vascular drug eluting stents. Includes consumables that are required uniquely for the deployment of the device
Radiofrequency, cryotherapy and microwave ablation probes and catheters	Except where used for complex Gastrointestinal Tract Endoscopy procedures. Includes consumables that are required uniquely for the deployment of the device
Rib Fixation Plates	Includes consumables that are required uniquely for the deployment of the device
Continuous Glucose Monitoring Systems	Includes consumables that are required uniquely for the deployment of the device
Liquid Embolic	Includes consumables that are required uniquely for the deployment of the device
Irreversible electroporation probes	Includes consumables that are required uniquely for the deployment of the device
Intracardiac pacemaker system	Includes consumables that are required uniquely for the deployment of the device
Wireless CRT-P (Cardiac Resynchronisation Therapy-Pacemaker) system	Includes consumables that are required uniquely for the deployment of the device

Note: the presence of devices on the above list does not automatically mean that commissioners will commission them. Some may be subject to prior approval

Procedures

Procedure	When to exclude	Local grouper processing	SUS national tariff processing
Head and Neck Reconstructive Surgery~	Pre-Processing at episode level	Do not run through grouper	Episodes need to be processed using '=' exclusion
Intracranial Telemetry%	Pre-Processing at episode level	Spells containing an episode with OPCS Code A111 or A112	Episodes need to be processed using '=' exclusion
Pelvic Reconstructions	Pre-Processing at episode level	ICD10 primary diagnosis one of: S321, S3210, S3211, S322, S3220, S3221, S323, S3230, S3231, S324, S325, S3250, S3251, S328 And OPCS code of Z75*, Z841 or Z842 And either 1. OPCS code of W195, W196, W198, W208, W209, W213, W214, W232, W236, W245, W248, W654, W655 or W677 OR 2. OPCS code of (W211, W212, W215, W218 or W219) and W281	Episodes need to be processed using '=' exclusion
PETCT (outpatient and direct access only)	Post-Processing	HRGs RN01A/B/C, RN02A/B and RN03A/B are excluded	The unbundled HRG will not have a mandatory tariff set
Soft Tissue Sarcoma	Pre-Processing at episode level	ICD10 (any position) diagnosis of: C40, C41, C47, C48, C49, or C79.5 And OPCS primary procedure code is not missing and is not a chapter X code, for example W052 "Implantation massive endoprosthetic replacement of bone".	Episodes need to be processed using '=' exclusion

~Surgery for the excision of and reconstruction for, upper aerodigestive tract, skull base, salivary and thyroid gland malignancies and non-malignancies
% including any subsequent cortical mapping and epilepsy surgery

Tests
Molecular Diagnostic tests -
NRAS/KRAS testing, BRAF Testing, KIT testing, ALK Testing (1), ALK Testing (2), Oncotype DX, PD-L1
EndoPredict and Prosigna

Prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease.